United Technologies Corp. (UTX) Financials Nov 17, 2014,
United Technologies Corp. (UTX) Financials Nov 17, 2014, 4:51 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for United Technologies Corp.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 52.59B 54.21B 58.09B 57.68B 62.65B
Cost of Goods Sold (COGS) incl. D&A 38.44B 39.07B 41.97B 41.81B 45.11B
COGS excluding D&A 37.18B 37.72B 40.63B 40.29B 43.29B
Depreciation & Amortization Expense 1.26B 1.36B 1.35B 1.52B 1.82B
Depreciation 911M 969M 949M 920M 1.11B
Amortization of Intangibles 347M 387M 398M 604M 710M
Gross Income 14.15B 15.13B 16.12B 15.86B 17.55B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 7.23B 7.61B 8.37B 8.57B 8.98B
Research & Development 1.56B 1.75B 2.06B 2.37B 2.53B
Other SG&A 5.67B 5.87B 6.31B 6.2B 6.45B
Other Operating Expense 0 0 0 0 0
Unusual Expense 889M 507M 375M 702M 427M
EBIT after Unusual Expense (889M) (507M) (375M) (702M) (427M)
Non Operating Income/Expense 435M 170M 721M 1.07B 1.05B
Non-Operating Interest Income 0 102M 179M 120M 137M
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense 705M 750M 673M 867M 1.01B
Gross Interest Expense 723M 767M 693M 886M 1.03B
Interest Capitalized 18M 17M 20M 19M 22M
Pretax Income 5.76B 6.54B 7.61B 6.91B 8.31B
Income Tax 1.58B 1.83B 2.23B 1.71B 2.24B
Income Tax - Current Domestic 293M 250M 527M 412M 671M
Income Tax - Current Foreign 837M 1.16B 1.37B 1.18B 1.33B
Income Tax - Deferred Domestic 411M 461M 555M 446M 298M
Income Tax - Deferred Foreign 40M (48M) (224M) (326M) (56M)
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 0 0 7M 0
Consolidated Net Income 4.18B 4.71B 5.37B 5.21B 6.07B
Minority Interest Expense 350M 338M 395M 360M 388M
Net Income 3.83B 4.37B 4.98B 4.85B 5.69B
Extraordinaries & Discontinued Operations 0 0 0 283M 35M
Extra Items & Gain/Loss Sale Of Assets 0 0 0 184M 4M
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 99M 31M
Net Income After Extraordinaries 3.83B 4.37B 4.98B 5.13B 5.72B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 3.83B 4.37B 4.98B 4.85B 5.69B
EPS (Basic) 4.17 4.82 5.58 5.53 6.35
Basic Shares Outstanding 917M 907.9M 892.3M 895.2M 901M
EPS (Diluted) 4.12 4.74 5.49 5.46 6.25
Diluted Shares Outstanding 929M 922.7M 906.8M 906.6M 915.1M
EBITDA 8.18B 8.88B 9.1B 8.81B 10.38B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Breaking New Ground in RNA Therapeutics Hey, in the world of biotech, landing a meaningful delivery system is like striking gold, and it seems Ractigen Therapeutics just found a shiny nugget. Their latest study on the LiCO™ platform, living and breathing in the pages of Molecular Therapy - Nucleic Acids, maps out a path to some serious therapeutic territory. These guys...
Continue Reading
Divorce isn't just a legal tangled mess; it's a financial minefield as well. Lindsey Obenhaus from Goranson Bain Ausley has beefed up her credentials with a Certified Divorce Financial Analyst® (CDFA®) designation, lending a sharper edge to her approach in divorce financials. When relationships turn sour, so do wallets, and Obenhaus aims to soften that blow for her...
Continue Reading
A Celebration of Veterans and Community Orland Hills is set to light up with a unique Veterans Day Bash on November 1, 2026. This isn't just your run-of-the-mill community gathering; it's an event that brings together veterans from all around for a day packed with resources, education, and a chance to connect with kindred spirits—all thanks to the collaboration between...
Continue Reading
Emerging AI Risks and Protective Measures AI in financial spaces is like walking a tightrope, there's potential but caution is crucial. Enter Enigmata, diving headfirst into this arena by shaking hands with the Finovifi Marketplace. Their aim? To bolster AI's promise without letting sensitive data slip through the cracks. Sentinel: A New Guard for Sensitive Data Let's not...
Continue Reading
Grappling with Medicare's Gaps Most folks hear Medicare and feel a sigh of relief—thinking it's a catch-all net for healthcare in your golden years. But hold on, when it comes to long-term care, Medicare's got more holes than Swiss cheese. Cindy Couyoumjian from Cinergy Financial lays it out pretty clear: Medicare doesn't cover what it calls 'custodial care'—you know,...
Continue Reading
Investors Face Rough Waters Okay, let’s dive into this latest mess at Lincoln Educational Services Corp. (NASDAQ:LINC). Things aren't smelling too rosy over at their headquarters. If you've got shares here, you’ll know what I mean. Back in early May, the folks running Lincoln threw a garden party talking up a 19.5% growth in student starts. Who wouldn’t get behind...
Continue Reading
A New Chapter for GDIT with a Veteran Leader Big shoes to fill? Nah, more like Amy Johnson was made for these shoes. Stepping up as president of General Dynamics Information Technology (GDIT) on November 3, she’s got 27 years of experience under her belt, all from General Dynamics' own backyard. This ain't her first rodeo. From tightrope-walking the perils of defense...
Continue Reading
Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...
Continue Reading
Surfactants and Epoxy Fuel Dimethylaminopropylamine Demand Hot off the presses, folks! Dimethylaminopropylamine, or DMAPA if you're into acronyms, is gearing up for a steady climb to a $731.9 million market value by the year 2035. That's quite the leap from the $452.6 million we saw back in 2025. According to Credence Research's latest estimates, this amine is hitching...
Continue Reading
Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...
Continue Reading
Top 5 Most Recently Viewed Articles
Infosys has officially linked arms with Sally Beauty Holdings, Inc. to kick off a major IT transformation initiative. The aim? Ramp up enterprise-scale efficiencies through hyper-automation, putting Sally Beauty on the fast track for growth and keeping it competitive in a crowded beauty sector. You know how it goes when firms try to modernize—it's always a mixed bag,...
Continue Reading
HYLENR and TakeMe2Space Team Up for Space Exploration HYLENR Technologies, a frontrunner in clean energy solutions, has embarked on an exciting collaboration with the innovative space-tech company, TakeMe2Space. This partnership aims to explore the potential of Low-Energy Nuclear Reaction (LENR) technology for space-based computing infrastructures. Innovative...
Continue Reading
Convoy of Hope's Major Initiative to Support Families As families across America face difficulties in making ends meet, there's a growing need for assistance. For just $10, it's possible to provide 30 meals to those in need. Feeding Families Nationwide In response to the increasing needs of these families, Convoy of Hope has launched an impressive initiative to deliver 10...
Continue Reading
The Flourishing Pulses Market Driven by Plant-Based Demand The global pulses market is experiencing significant growth, with projections estimating its value to rise from USD 78.0 billion in the coming years to USD 135.2 billion. This increase represents an impressive CAGR of 5.7% throughout the forecast period. The motivation behind this expansion is largely attributed...
Continue Reading
Windtree's Istaroxime Patent Issuance: A Game Changer for Heart Failure Windtree Therapeutics, Inc., a pioneering biotech firm, recently celebrated a watershed moment with the issuance of a patent for istaroxime by the United States Patent and Trademark Office. This patent pertains to a unique intravenous formulation aimed at treating acute heart failure, an ailment that...
Continue Reading